<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03050437</url>
  </required_header>
  <id_info>
    <org_study_id>2012-12-035</org_study_id>
    <nct_id>NCT03050437</nct_id>
  </id_info>
  <brief_title>A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI</brief_title>
  <official_title>A Randomized, Open Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Pemetrexed Until Progression Versus Pemetrexed Alone Until Progression in Non-small Cell Lung Cancer Patients Who Have Progressed on First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has not been established whether platinum-based doublets is better than single agent&#xD;
      chemotherapy in EGFR mutant NSCLC patients who failed first-line EGFR TKI.&#xD;
&#xD;
      In this prospective trial, the investigators try to evaluate whether the progression-free&#xD;
      survival of pemetrexed/cisplatin (PC) regimen is longer than that of pemetrexed single(P)&#xD;
      regimen in NSCLC patients who have progressed after first line treatment of EGFR-TKI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Pem/Cis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pem/Cis IV every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pem alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pem IV alone every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cisplatin is added to Pem/cis arm</description>
    <arm_group_label>Pem/Cis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pem is applied to both arms</description>
    <arm_group_label>Pem alone</arm_group_label>
    <arm_group_label>Pem/Cis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed nonsquamous NSCLC with activating EGFR mutation (on exon 19&#xD;
             deletion or exon 21 L858R mutation)&#xD;
&#xD;
          -  Stage IIIb, IV or recurrent NSCLC (AJCC 7th criteria)&#xD;
&#xD;
          -  Age ≥ 20 years&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  At least one measurable lesion by RECIST 1.1&#xD;
&#xD;
          -  Progression after first line treatment with EGFR TKIs for advanced NSCLC&#xD;
&#xD;
          -  Asymptomatic brain metastasis or symptomatic brain metastasis treated with local&#xD;
             treatment such as operation, whole brain radiotherapy, or gamma-knife surgery&#xD;
&#xD;
          -  At least 2 weeks later after whole brain radiotherapy or palliative radiotherapy&#xD;
&#xD;
          -  Adequate renal function: estimated creatinine clearance ≥ 45 mL/min&#xD;
&#xD;
          -  Organ function as evidenced by the following; Absolute neutrophil count &gt; 1.5 x 109/L;&#xD;
             platelets &gt; 100 x 109/L; total bilirubin ≤1.5 UNL; AST and/or ALT &lt; 3 UNL, in case of&#xD;
             known hepatic metastasis, AST/ALT&lt; 5 UNL&#xD;
&#xD;
          -  Written informed consent form&#xD;
&#xD;
          -  No other previous systemic chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or&#xD;
             arrhythmia&#xD;
&#xD;
          -  Patients with post-obstructive pneumonia or uncontrolled serious infection&#xD;
&#xD;
          -  Pregnant or nursing women (Women of reproductive potential have to agree to use an&#xD;
             effective contraceptive method)&#xD;
&#xD;
          -  Uncontrolled symptomatic brain metastasis&#xD;
&#xD;
          -  Presence of third space fluid which cannot be controlled by drainage&#xD;
&#xD;
          -  Prior history of malignancy within 5 years from study entry except for adequately&#xD;
             treated basal cell or squamous cell skin cancer or in situ cervical cancer,&#xD;
             well-treated thyroid cancer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung-Ju Ahn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ju Yeon Park, RN</last_name>
    <phone>82-2-3410-3459</phone>
    <email>jy1223.park@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Ju Ahn, Ph.D.</last_name>
      <phone>822-3410-1795</phone>
      <email>silkahn@skku.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Myung-Ju Ahn</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Failed in First Line EGFR-TKI</keyword>
  <keyword>EGFR Activating Mutation</keyword>
  <keyword>Pemetrexed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

